Ionis Pharmaceuticals vs Regeneron Pharmaceuticals: why the prices moved differently

• ▲

  Sefaxersen hits Phase 3 goal in IgA nephropathy Partner Roche reported that sefaxersen met its main Phase 3 goal in IgA nephropathy, a kidney disease, with strong protein reductions and no new safety issues. Ionis gets milestone payments and royalties, and the win shows its RNA technology works in a large market.

  This is a new clinical win that directly lifts confidence in Ionis's platform and future royalty revenue.

• ▲

  Ulefnersen succeeds in rare FUS-ALS Ionis and Otsuka said ulefnersen met its main late-stage goal in FUS-ALS, a rare inherited form of ALS, improving function and survival. No approved treatment targets this genetic cause, and they will seek accelerated approval. Ionis earns milestones and royalties.

  A second new Phase 3 success in a different disease area broadens the pipeline and adds another potential revenue stream.

Based on 6 stories →

• ▲

  FDA approves Zanvastro, first Alexander disease treatment The FDA approved Ionis' Zanvastro (zilganersen) as the first-ever treatment for Alexander disease, a rare neurological condition. This is a new commercial product and validates Ionis' RNA-targeting platform, giving the company a new revenue stream and lifting investor confidence.

  This is a major new approval that directly boosts Ionis' revenue prospects and pipeline credibility.

• ▼

  Partner Novartis' pelacarsen fails Phase 3 heart trial Novartis' pelacarsen, discovered by Ionis and licensed to Novartis, failed its Phase 3 Lp(a)HORIZON trial. It lowered Lp(a) but did not reduce cardiovascular events. Ionis shares fell 6.18% after hours. This is a setback for a partnered asset and raises doubts about the Lp(a) approach.

  This is the main negative event of the period, directly hitting Ionis' pipeline and stock price.

• ▼

  Analysts see limited financial impact from pelacarsen failure BofA and Citi analysts said the pelacarsen failure has low-single-digit downside for Ionis and should not affect 2026 guidance. Citi maintains a Buy rating and $100 target. This suggests the market may be overreacting, but the failure still removes a potential blockbuster.

  It provides context on the financial materiality of the pelacarsen failure, helping investors gauge the real impact.

• ▼

  Wainua Phase 3 failure in ATTR-CM adds to RNA silencer doubts Full Phase 3 data for Wainua (with AstraZeneca) failed to meet its primary goal in ATTR-CM. An analyst said oral stabilizers may be superior to subcutaneous silencers. This hurts Alnylam and has negative read-through for Ionis' RNA silencer technology.

  It is a separate negative trial result that questions the broader RNA silencer approach Ionis uses.

Based on 6 stories →

• ▲

  Q2 earnings beat and guidance reaffirmed Ionis reported a smaller-than-expected loss and higher revenue, and kept its 2026 sales and loss forecasts unchanged. That tells investors the core business is on track, which supports the stock even after recent trial setbacks.

  This is the period's main new positive fundamental event and directly counters the negative narrative.

• ▼

  Arrowhead's rival lipid drug succeeds, pressuring Ionis Arrowhead's plozasiran cut triglycerides by about 80% in a late-stage trial, beating Ionis's competing olezarsen. If approved, it could take market share in the same severe high-triglyceride market, making Ionis's future sales outlook less certain.

  This is a new competitive threat that directly affects Ionis's key growth market.

• ▲

  ARK ETF buys $15.3 million of Ionis shares Cathie Wood's ARK fund bought $15.3 million of Ionis stock after the trial-driven selloff. A well-known investor stepping in can steady sentiment and signal that some see the drop as overdone, though it does not change the company's fundamentals.

  This is a new capital-flow signal that helps explain the stock's stabilization after the crash.

Based on 6 stories →

• ▼

  Wainua heart trial failure and Roche's Huntington's exit Ionis and AstraZeneca's Wainua failed a Phase 3 heart trial, and Roche scrapped two partnered Huntington's programs. Shares fell about 29% in two days, wiping out a large expected revenue source and shaking confidence in the pipeline.

  This is the biggest new negative event, directly causing a sharp price drop and removing a major future revenue driver.

• ▼

  Securities fraud investigations launched Law firms Hagens Berman and Pomerantz are investigating whether Ionis misled investors about the Wainua trial's design and prospects. Legal uncertainty can pressure the stock and distract management, even if no charges are filed.

  New legal probes add a fresh layer of risk and uncertainty that can weigh on the stock price.

• ▼

  Alzheimer's drug misses primary endpoint in Phase 2 Biogen and Ionis's diranersen missed its main goal in a mid-stage Alzheimer's trial, though it showed some benefit on secondary measures. The miss is a setback for a partnered pipeline asset, but Phase 3 plans continue.

  This is a new clinical disappointment that adds to negative sentiment around Ionis's partnered programs.

• ▲

  Zilganersen licensed to Recordati and Angelman enrollment complete Ionis licensed zilganersen for Alexander disease outside the U.S. to Recordati for $30 million upfront plus royalties, and completed enrollment in the pivotal Phase 3 trial for its Angelman syndrome drug. These show pipeline progress and bring in cash.

  These are new positive developments that highlight Ionis's pipeline strength and near-term revenue potential, offering a counterweight to the negative news.

Based on 9 stories →

• ▲

  FDA approves Tryngolza for severe high triglycerides The FDA approved Tryngolza as the first treatment for severe hypertriglyceridemia, a condition affecting nearly 3 million Americans. It cuts triglycerides up to 72% and pancreatitis risk up to 91%. Ionis will launch it itself in July, opening a large new market and potential revenue stream.

  This is a major new approval that expands Ionis's commercial opportunity and drives the stock up.

• ▼

  Eplontersen fails Phase 3 ATTR-CM trial Ionis and AstraZeneca's eplontersen missed its primary endpoint in the CARDIO-TTRansform trial for ATTR-CM, a heart condition. The drug failed to reduce cardiovascular deaths or events. This removes a large expected revenue opportunity and caused Ionis shares to drop sharply.

  This is a major clinical failure that directly hurts Ionis's growth prospects and stock price.

• ▼

  Ionis stock plunges on eplontersen news Following the trial failure, Ionis shares fell as much as 19% intraday. The setback also lifted rival ATTR-CM drugs from Alnylam and BridgeBio, highlighting lost competitive ground. The full data will be presented in August, but the primary endpoint miss is a clear negative.

  This shows the immediate market reaction and competitive impact of the trial failure.

Based on 6 stories →

• ▲

  Sanofi alliance expansion brings $1B upfront and pipeline growth Sanofi will pay Regeneron $1 billion upfront plus up to $7 billion in milestones for four new antibodies, expanding the partnership that made Dupixent. This boosts Regeneron's cash and pipeline, but the deal left Dupixent profit-sharing unchanged, disappointing some investors and causing a 4% share drop.

  This is the period's biggest capital and pipeline event, directly affecting Regeneron's finances and investor sentiment.

• ▲

  Trevogrumab preserves muscle in Phase 2 obesity trial Regeneron's trevogrumab preserved about 70% of muscle loss caused by semaglutide in a Phase 2 trial. This opens a potential new obesity treatment, a large market, and shows Regeneron's research engine is producing promising results, which supports the stock.

  A positive clinical readout in a major new market area is a key driver of future growth expectations.

• ▼

  Kodiak eye drug matches Eylea with less frequent dosing Kodiak Sciences reported Phase 3 data showing its eye drugs matched Eylea's vision results with dosing every six months versus Eylea's eight weeks. This threatens Regeneron's key Eylea franchise, which is already facing biosimilar competition, and could pressure future sales.

  Eylea is a major revenue source, and new competition with better convenience could erode Regeneron's market share.

• ▲

  Pozelimab-cemdisiran highlighted as top emerging PNH therapy An analyst forecast named Regeneron's pozelimab plus cemdisiran as the emerging PNH therapy expected to generate the highest revenue, with Phase 3 results due late 2026 or early 2027. This supports hopes for a new blockbuster beyond current drugs.

  It points to a future growth driver and validates Regeneron's pipeline in a rare disease market.

Based on 7 stories →

• ▲

  Q2 beat on Dupixent and high-dose Eylea Regeneron beat second-quarter estimates: revenue rose 17% to $4.29 billion and adjusted profit was $14.29 a share. Dupixent sales jumped 38% to about $6 billion, and U.S. high-dose Eylea sales rose 52%. Strong demand for these key drugs lifts profit and supports the stock.

  This is the period's biggest positive fundamental driver of REGN's value.

• ▲

  Sanofi repayment improves margins Regeneron fully repaid the Sanofi Development Balance. An RBC analyst said this should improve margins and make second-half numbers look much better. Paying off this obligation frees up cash and boosts future profit, a positive for the stock.

  It is a concrete capital event that improves future profitability.

• ▲

  FDA approves Pasatru for rare FOP disease The FDA approved Pasatru (garetosmab) for fibrodysplasia ossificans progressiva, a rare bone disease, based on a Phase 3 trial showing 90% fewer new lesions. The patient group is tiny, so near-term sales are modest, but it proves Regeneron's drug platform still produces new approved medicines.

  A new FDA approval is a fresh product and pipeline milestone for REGN.

• ▼

  Securities class action over failed melanoma trial A securities class action alleges Regeneron misled investors about the Phase 3 Fianlimab-Libtayo melanoma trial, which failed its main goal and wiped out $11 billion in market value. The lead plaintiff deadline is September 14. Legal costs and uncertainty weigh on the stock.

  This is the main negative overhang on REGN this period.

Based on 7 stories →

• ▲

  Cemdisiran regulatory progress FDA granted Priority Review and EMA accepted filings for cemdisiran in generalized myasthenia gravis. If approved, it would be the first siRNA treatment and only subcutaneous option dosed four times a year, opening a new revenue stream. FDA decision expected November 2026.

  This is a new positive regulatory catalyst that could drive future revenue and investor optimism.

• ▼

  Failed melanoma trial and securities lawsuits Regeneron faces multiple class action lawsuits alleging it misled investors about its Phase 3 Fianlimab-Libtayo melanoma trial, which failed to meet its primary endpoint. The trial failure wiped out $11 billion in market value, and the lawsuits create legal overhang and reputational risk.

  This is a new negative development that directly impacts Regeneron's stock through legal uncertainty and investor confidence.

• ▼

  Pipeline setbacks and mixed trial results Longleaf Partners Fund reported Regeneron was a Q2 detractor after disappointing trial results for a pipeline drug. The fund noted only one of three key pipeline readouts succeeded, below expectations. This highlights execution risk in Regeneron's drug development, weighing on sentiment.

  This new analyst commentary underscores pipeline challenges that could pressure the stock.

Based on 7 stories →

• ▲

  CytomX collaboration expands cancer pipeline Regeneron expanded its cancer drug partnership with CytomX, paying $37 million upfront and potentially up to $4 billion in milestones. This gives Regeneron access to new technology for next-generation cancer therapies, which could boost future revenue and growth prospects.

  This is a new deal that adds to Regeneron's pipeline and potential future earnings.

• ▲

  Dupixent sales surge 30.8% Sanofi reported that Dupixent, co-developed with Regeneron, generated €4.17 billion in first-quarter sales, up 30.8% from a year ago. This strong growth directly boosts Regeneron's revenue and profit, as Regeneron shares in the profits.

  Dupixent is a major revenue driver for Regeneron, and its strong sales growth directly impacts Regeneron's financial performance.

• ▲

  FDA and EMA accept cemdisiran filings Regeneron's new drug cemdisiran for generalized myasthenia gravis was accepted for review by the FDA and EMA. The FDA granted Priority Review with a decision expected by November 2026. If approved, it could be a first-in-class treatment, adding a new revenue stream.

  This regulatory milestone brings Regeneron closer to launching a new drug, which could drive future sales.

• ▼

  AbbVie acquires Apogee, increasing competition AbbVie agreed to buy Apogee Therapeutics for $10.9 billion, gaining a potential competitor to Regeneron's Dupixent. This could pressure Dupixent's market share in inflammatory diseases like atopic dermatitis and asthma, posing a long-term risk to Regeneron's revenue.

  This is a new competitive threat that could impact Regeneron's key product, Dupixent.

Based on 7 stories →